MASP-2 Inhibitory Agents for Selective Complement Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for ischemia-reperfusion injury and stroke lack effective methods to inhibit complement activation, leading to significant tissue damage and neurological deficits, with existing treatments either being non-specific or having limited efficacy.
Innovation Solution
Development of MASP-2 inhibitory agents, such as antibodies or peptides, that specifically target MASP-2-dependent complement activation, allowing for the inhibition of the lectin-dependent pathway while preserving the classical pathway, thereby reducing tissue damage and neurological deficits in ischemia-reperfusion injuries and strokes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If MASP-2 inhibitory agents are used to selectively inhibit complement activation, then tissue damage is reduced, but the ability to handle immune complexes may be compromised
Solution Approach 1:
The invention segments the complement system into distinct pathways (classical and lectin/alternative) and selectively inhibits only the MASP-2-dependent lectin/alternative pathway while preserving the classical pathway. This is achieved through specific inhibition of MASP-2 enzyme activity, allowing differential control of complement activation routes to reduce tissue damage while maintaining essential immune functions.
Solution Approach 2:
The invention applies local quality by creating selective inhibition at the MASP-2 enzyme level rather than broad complement suppression. The inhibitory agents (monoclonal antibodies, peptides, small molecules) specifically target MASP-2 activity, creating localized precision inhibition that spares other complement pathways and maintains their protective functions including immune complex handling.
2Object-affected harmful factors
If existing complement inhibition therapies are used, then complement activation is reduced, but they lack specificity and have limited efficacy
Solution Approach 1:
The invention introduces MASP-2 as a specific intermediary target between complement activation and tissue damage. By developing inhibitory agents that specifically bind to or inhibit MASP-2 enzyme activity, the invention creates a precise intervention point in the complement cascade, enabling selective blockade of the lectin/alternative pathway while preserving classical pathway functionality.
Solution Approach 2:
The invention changes the parameter of inhibition specificity by targeting MASP-2 enzyme activity rather than broader complement components. Through various inhibitory mechanisms (antibody binding, peptide competition, small molecule inhibition), the invention modifies the activation state of MASP-2 specifically, creating precise control over complement pathway selection and activation thresholds.
Data Source
AI summary
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.